NEW YORK – Lithuanian single-cell sample preparation firm Atrandi Biosciences said Tuesday that it has raised a $25 million Series A financing round.
Lux Capital led the round, joined by Vsquared Ventures, Practica Capital, Metaplanet, and GRIDS Capital.
In a statement, Atrandi said the funding would "accelerate the company's expansion into the US market, support the growth of its semipermeable capsule technology, and advance new product development."
Founded in 2016 and formerly known as Droplet Genomics, Atrandi said its technology encapsulates single cells in permeable compartments, "allowing researchers to conduct bulk-like reactions while maintaining single-cell resolution."
In 2023, Atrandi raised $4.8 million led by Vsquared Ventures. It has more than 65 employees and plans to open an office in Boston this year.
Last year, Atrandi launched the Flux instrument and barcoding reagents for microbial genomics. The firm also offers the Styx platform for fluorescence-activated droplet and capsule detection, as well as Onyx, a microfluidic system that supports droplet generation and manipulation.